Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus EMGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus EMGEL.
BENZAMYCIN vs EMGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 mL/min).
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination.
Category C
Category C
Topical Antibiotic
Topical Antibiotic